CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Medpace Q3 2026 diluted EPS climbs 25% to $4.84

By Public Technologies
  • Medpace’s third-quarter 2026 GAAP diluted earnings rose 25% year over year to $4.84 per share.
  • Revenue increased 9% year over year to $716 million.
  • Net new business awards climbed 11% year over year to $873.4 million.
  • A new $1 billion stock repurchase authorization runs through December 31, 2028, replacing the previous authorization.
  • Full-year 2026 GAAP diluted earnings are forecast at $17.97 to $18.32 per share.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medpace Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261021758492) on October 21, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk